Gilead To Price Harvoni Close To Cost Of Sovaldi Plus Interferon & Ribavirin

Gilead Sciences will price its soon-to-be-approved hepatitis C combination drug Harvoni close to the near-$100,000 cost of the current 12-week regimen of Sovaldi plus pegylated interferon and ribavirin, Gilead President and CEO John Milligan said Wednesday (Oct. 1). Insurance companies and others, including employers, hospitals and state officials, are pressuring Gilead to lower Sovaldi's price, and they anxiously await to see how the company prices Harvoni. Hepatitis C patients without scarring of the liver and with low viral loads will...